SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals-Reference-Cited by-同舟云学术

SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals

Published:2022-09-01 Issue:1 Volume:13 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Sano Kaori^ORCID,Bhavsar Disha^ORCID,Singh Gagandeep^ORCID,Floda Daniel,Srivastava Komal,Gleason Charles,Amoako Angela A.,Andre Dalles,Beach Katherine F.,Bermúdez-González Maria C.,Cai Gianna,Cognigni Christian,Kawabata Hisaaki,Kleiner Giulio,Lyttle Neko,Mendez Wanni,Mulder Lubbertus C. F.,Oostenink Annika,Raskin Ariel,Rooker Aria,Russo Kayla T.,Salimbangon Ashley Beathrese T.,Saksena Miti,Sominsky Levy A.,Tcheou Johnstone,Wajnberg Ania,Carreño Juan Manuel,Simon Viviana^ORCID,Krammer Florian^ORCID,

Abstract

AbstractImmune responses at the respiratory mucosal interface are critical to prevent respiratory infections but it is unclear to what extent antigen specific mucosal secretory IgA (SIgA) antibodies are induced by mRNA vaccination in humans. Here we analyze paired serum and saliva samples from patients with and without prior coronavirus disease 2019 (COVID-19) at multiple time points pre and post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination. Our results suggest mucosal SIgA responses induced by mRNA vaccination are impacted by pre-existing immunity. Indeed, vaccination induced a minimal mucosal SIgA response in individuals without pre-exposure to SARS-CoV-2 while SIgA induction after vaccination was more efficient in patients with a history of COVID-19.

Funder

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary

Link

https://www.nature.com/articles/s41467-022-32389-8.pdf

Reference30 articles.

1. WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard with Vaccination Datahttps://covid19.who.int/ (WHO, accessed 13 July 2022).

2. Martines, R. B. et al. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States, Vol. 26 (9)—September 2020—CDC. Emerg. Infect. Dis.26, 2005–2015 (2020).

3. Brandtzaeg, P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine25, 5467–5484 (2007).

4. Suzuki, T. et al. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proc. Natl Acad. Sci. USA112, 7809–7814 (2015).

5. Murphy, B. R. & Clements, M. L. The systemic and mucosal immune response of humans to influenza A virus. Curr. Top. Microbiol. Immunol.146, 107–116 (1989).

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva;Frontiers in Immunology;2024-02-05

2. SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters;Journal of Virology;2024-02

3. Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages;Proceedings of the National Academy of Sciences;2024-01-09

4. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters;Vaccine;2024-01

5. Comparison of Omicron Breakthrough Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in Mucosal and Systemic Humoral Immunity;Mucosal Immunology;2024-01